ストックスクリーナーアプリを入手
17.60
2.98%
0.51
前日終値:
$17.09
開ける：
$17.26
24時間の取引高:
1.12M
Relative Volume:
0.50
時価総額：
$3.26B
収益：
$1.03B
当期純損益:
$-297.43M
株価収益率:
-10.90
EPS:
-1.615
ネットキャッシュフロー:
$-261.39M
1週間 パフォーマンス:
-3.35%
1か月 パフォーマンス:
-10.75%
6か月 パフォーマンス:
-46.37%
1年 パフォーマンス:
-49.79%
1日の値動き範囲:
$17.26
$17.82
1週間の範囲:
$16.96
$18.80
52週間の値動き範囲:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Compare LEGN vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
17.60 | 3.16B | 1.03B | -297.43M | -261.39M | -1.615 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | ダウングレード | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-10-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Hudson Bay Capital Management LP Has $7.17 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright - MarketBeat
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright - MarketBeat
Braidwell LP Decreases Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
ArrowMark Colorado Holdings LLC Cuts Position in Axis Capital Holdings Limited $AXS - Defense World
UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
916,443 Shares in Bath & Body Works, Inc. $BBWI Bought by Capital International Investors - Defense World
CLEAR Secure, Inc. (NYSE:YOU) Receives Average Recommendation of “Hold” from Analysts - Defense World
Royal Bank Of Canada Lowers Legend Biotech (NASDAQ:LEGN) Price Target to $62.00 - Defense World
Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire - AASTOCKS.com
RBC Capital lowers Legend Biotech stock price target on model updates By Investing.com - Investing.com South Africa
RBC Capital lowers Legend Biotech stock price target on model updates - Investing.com India
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong Q4 results - Investing.com India
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity - Investing.com
Jefferies reiterates Legend Biotech stock rating on Carvykti sales - Investing.com India
Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Q4 Earnings Call Highlights - Yahoo Finance
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech earnings on deck as profitability looms - Investing.com South Africa
Triata Capital Ltd Purchases 54,300 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Raymond James reiterates Legend Biotech stock rating after rival approval - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Trading Up 5.5%Here's Why - MarketBeat
Artisan Partners Limited Partnership Purchases 425,684 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Westfield Capital Management Co. LP Lowers Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Nuclear Stocks To Research – February 23rd - Defense World
Raymond James reiterates Legend Biotech stock rating on valuation gap - Investing.com South Africa
Etsy (NYSE:ETSY) Stock Price Up 6.6% on Earnings Beat - Defense World
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions - Finviz
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) - Finviz
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (NASDAQ:LEGN) Downgraded by Rothschild & Co Redburn to “Neutral” - Defense World
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowTime to Sell? - MarketBeat
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss - Finviz
82,516 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Mutual of America Capital Management LLC - MarketBeat
Legend Biotech stock hits 52-week low at $18.07 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $18.07 - Investing.com
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):